Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from ARGX

New S&P 500 Entrant Airbnb And DKNG Lead 5 Stocks Near Buy Points

Airbnb, which is set to join the S&P 500 on Monday, and DKNG lead a watch list of stocks poised to make moves if the stock market can find its footing.

Investors Business Daily

Top AI Stock ANET Leads 5 Stocks Near Buy Points In Tough Market

AI stock standout Arista Networks and Netherlands-based biotech Argenx lead this weekend's watch list of 5 stocks holding in or near buy range.

Investors Business Daily

Argenx Beats Earnings Expectations As Sales Of 'Megabuster' Drug Grow 260%

Argenx is up around 40% in 2023. On Thursday, the company reported second-quarter revenue ballooning 230% as sales of its lone product ramp up.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

The Multibillion-Dollar Opportunity That Sent Argenx Flying 28% Into A Breakout

An Argenx drug beat expectations in a study of patients with a progressive nerve disorder and ARGX stock catapulted to a record high.

Investors Business Daily

SVB Sees Strategic Value In This Stock As M&A Target In Autoimmune Space

SVB Securities initiated coverage on Argenx SE (NASDAQ:ARGX) with an Outperform rating and a $404 price target. Argenx's Vyvgart (efgartigimod) is a neonatal Fc-Receptor (FcRn) antagonist that selectively reduces IgG levels and has the potential to address numerous IgG-mediated autoimmune diseases. According to the analyst, Argenx has demonstrated strong early launch execution for Vyvgart…

Benzinga

Argenx's Vyvgart Meets Primary Goal In Late-Stage Bleeding Disorder Study

Argenx SE's (NASDAQ:ARGX) Phase 3 ADVANCE trial of Vyvgart (efgartigimod alfa-fcab) in adults with primary immune thrombocytopenia (ITP) met its primary endpoint. The ADVANCE trial enrolled 131 adult patients with chronic and persistent ITP. Patients were heavily pretreated. A higher proportion of patients with chronic ITP receiving VYVGART (17/78; 21.8%) than placebo…

Benzinga

Argenx's Subcutaneous Efgartigimod At Par With Intravenous Administration In Neuromuscular Disorder

Argenx SE (NASDAQ: ARGX) ) has

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Stock Market

4,629 stories

Read news from The Economist, FT, and more,
with one subscription

Places

Netherlands

2,027 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.